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Abstract 
The pedunculopontine nucleus (PPN) is a rostral brainstem structure that has extensive 
connections with basal ganglia nuclei and the thalamus. Through these the PPN contributes to 
neural circuits that effect cortical and hippocampal activity. The PPN also has descending 
connections to nuclei of the pontine and medullary reticular formations, deep cerebellar nuclei 
and the spinal cord. Interest in the PPN has increased dramatically since it was first suggested to 
be a novel target for treating patients with Parkinson’s disease (PD) who are refractory to 
medication. However, application of frequency-specific electrical stimulation of the PPN has 
produced inconsistent results. A central reason for this is that the PPN is not a heterogeneous 
structure. Here we review current knowledge of the neurochemical identity and topographical 
distribution of neurons within the PPN of both humans and experimental animals, focusing on 
studies that used neuronally-selective targeting strategies to ascertain how the neurochemical 
heterogeneity of the PPN relates to its diverse functions in relation to movement and cognitive 
processes. If the therapeutic potential of the PPN is to be realized, it is critical to understand the 
complex structure-function relationships that exist here. 
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Introduction 
The pedunculopontine nucleus (PPN), synonymous with the terms pedunculopontine tegmental 
nucleus (PPTg or PPT), tegmental pedunculopontine nucleus (TPP) or nucleus tegmenti 
pedunculopontinus (NTPP), is a brain structure that has been highly conserved in the animal 
kingdom throughout evolution. In humans, it is located in the caudal pontomesencephalic 
tegmentum, between the substantia nigra (SN) and the parabrachial nuclei, lying lateral to the 
ascending limb of the superior cerebellar peduncle. Its rostral end commences just below the red 
nucleus, dorsal to the SN, continuing caudally to the level of the locus coeruleus. Medially, the 
PPN is bounded by fibers of the brachium conjunctivum. The medial lemniscus forms the lateral 
and ventral borders, with the cuneiform and subcuneiform nuclei that form the dorsal aspect.  
The PPN occupies a strategic position for modulating a range of physiological and behavioral 
functions (reviewed by Gut and Winn 2016) (Figure 1). It has a strategic position in basal 
ganglia circuitry, having reciprocal connections with key output nuclei, including direct output to 
sites of motor and autonomic control in the brainstem, cerebellum and spinal cord. This 
realization has encouraged the belief that the PPN is essentially a basal ganglia output station, 
but its multiple other connections suggest wider functionality. For instance, it has limbic inputs 
from the basal forebrain/ventral pallidal region as well as the lateral hypothalamus, and 
multimodal sensory input from the brainstem and midbrain. Indeed, PPN neurons respond to 
auditory stimuli, in particular those with very short latencies (~8 ms); indicating that very fast 
sensory processing happens here (Dormont and others 1998). Perhaps the single largest PPN 
connection is with the thalamus, via which the PPN exerts significant influence over cortical 
activity (Heckers and others 1992). 
Extensive neuronal death occurs within the PPN during the early stages of neurodegenerative 
diseases such as Parkinson's disease (PD), progressive supranuclear palsy (PSP), dementia with 
Lewy bodies (DLB) and multiple system atrophy (MSA) (Hirsch and others 1987; Pienaar and 
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others 2013). The activity of the remaining neurons is also changed due to disturbed basal 
ganglia outflow (Mitchell and others 1989). These pathological data provided the rationale for 
targeting the PPN for alleviating specific symptoms of advanced PD by using deep brain 
stimulation (DBS), where electrodes are implanted unilaterally or bilaterally (Plaha and Gill 
2005; Mazzone and others 2005; Stefani and others 2007; for recent reviews see Collomb-Clerc 
and Welter 2015; Mazzone and others 2016). PPN-DBS has been reported as alleviating 
dopamine-resistant axial motor abnormalities, including freezing, gait abnormalities and postural 
abnormalities (Collomb-Clerc and Welter 2015) (Figure 2; Table 1), although some studies 
showed that gait amelioration was only transient and there were no motor benefits (Ferraye and 
others 2010). PPN-DBS induced amelioration of non-motor symptoms, particularly 
improvements in executive functions, verbal fluency (Zanini and others 2009), working memory 
and sleep architecture (Alessandro and others 2010). The variety of outcomes from PPN-DBS is 
striking. One possibility for this is that the relatively small numbers of PPN-DBS studies 
performed so far, with varied patient inclusion criteria, stage of illness and electrode placement 
(to entail different likelihoods of stimulating local fibre systems) mean that varied outcomes are 
inevitable. Moreover, the fact that there is neuronal loss from the PPN will add a further 
complicating factor to the likelihood of achieving positive clinical outcomes from DBS in PD 
cases. On the other hand, the variability might reflect observations from experimental animal 
studies showing diverse functions for PPN neurons that cover motor and also cognitive domains 
(reviewed by Gut and Winn 2016). 
A major obstacle preventing PPN-DBS from achieving its full therapeutic potential is 
determining the optimal placement for stimulating electrodes and selection of appropriate 
stimulation parameters. Computational modeling suggests that errors as small as 1 mm for 
surgically placing electrodes could produce substantial decrements in PPN activation (Zitella and 
others 2013). Furthermore, side-effects such as paraesthesia and oscillopsia may result from 
unintended stimulation of surrounding structures (Ferraye and others 2009). To guide correct 
  5   
placement, studies of the topographical organization of the human PPN are needed. For instance, 
electrode placement into the caudal versus rostral PPN may explain variance in clinical effects. 
Also, studies using experimental animals (discussed below) showed that PPN sub-regions have 
different functions. Hence, given the subtlety of internal organization, it is highly likely that 
stimulating PPN subfields could result in different but potentially predictable outcomes. Here we 
summarize the current state of knowledge, first regarding the neurochemical composition and 
topological distribution of neurons in the PPN and secondly the behavioral functions of the PPN, 
relating PPN structure and function to potential involvement in PD.  
The neurochemical composition of the PPN 
Classical neurotransmitters 
The PPN of humans, non-human primates and rodents contain neurons expressing the 
neurotransmitters acetylcholine (ACh) (Hirsch and others 1987; Pienaar and others 2013), 
gamma-aminobutyric acid (GABA), glutamate (Wang and Morales 2009; Mena-Segovia and 
others 2009; Barroso-Chinea and others 2011; Martinez-Gonzalez and others 2012), and glycine 
(Pienaar and others 2013). ACh-producing cholinergic neurons are the ones that have been most 
closely investigated, with recent studies that identified previously unknown parcelation of 
cholinergic inputs to the midbrain dopamine-containing neurons (Dautan and others 2016a) as 
well as direct cholinergic projections to the striatum (Dautan and others 2014; Dautan and others 
2016b). Such studies are making it increasingly clear that both cholinergic and non-cholinergic 
neurons contribute significantly to the PPN’s control over behavior and cortical state (Ros and 
others 2010; Petzold and others 2015). 
PPN neurons co-expressing classical neurotransmitters have also been described, although 
this does not necessarily imply co-release (Stamatakis and others 2013). In the cat PPN, co-
reactivity for choline acetyltransferase (ChAT) (the transferase enzyme responsible for ACh 
synthesis and therefore an immunohistochemical marker for cholinergic neurons) and GABA 
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was seen in neuronal somata, dendrites and axon terminals (Jia and others 2003). In addition, 
Lavoie and Parent (1994) found ChAT and glutamate co-expression within the PPNs of squirrel 
monkeys, as well as intermingling of cholinergic and noradrenergic dendrites. Similar 
connectivity was described in rats between serotonergic neurons projecting from the dorsal raphe 
and cholinergic and non-cholinergic PPN neurons (Steininger and others 1997), while analysis of 
guinea pig PPNs found histaminergic afferents from the posterior hypothalamus (Khateb and 
others 1990). Demonstrations of cholinergic–noradrenergic–serotonergic–histaminergic 
interactions reinforce the long-standing idea that the PPN plays a role in the ascending reticular 
activating system (ARAS).  
Neuropeptides 
Neurons projecting to or from the PPN express various neuropeptides, including 
orexin/hypocretin (HCRT), galanin, substance P, enkephalin and dynorphin. Darwinkel and 
colleagues (2014) showed double-labelling of nitric oxide synthase (NOS) and orexin-1 
receptors in neuronal cell bodies and fibers of the mouse PPN, while Peyron and others (1998) 
showed that the PPN receives HCRT input from hypothalamic neurons. Double-labelling 
immunohistochemistry in rat PPN detected intermingling of fibers containing HCRT and 
dopamine-beta-hydroxylase, a marker of noradrenergic neurons. HCRT neurons are implicated 
in regulating arousal, reward and motivation, the sleep-wake cycle and appetite (Chen and others 
2015); functions the PPN is implicated in, whilst such neurons are also affected in progressive 
PD (Drouot and others 2003). Galanin localises in human PPN neurons containing the 
neurokinin, substance P (Gai and others 1993). A substantial loss of substance P-containing PPN 
neurons was seen in the post-mortem PPNs of PD patients (Halliday and others 1990), although 
the impact this has on motor-, cognitive- and autonomic nervous system functions in PD patients 
remain to be determined. Also of significance, cholinergic neurons in the PPN and the adjacently 
lying laterodorsal tegmental nucleus (LDT) are unique in the pontomesencephalic tegmentum for 
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expressing urotensin II (UII) receptors. Not only does urotensin in the PPN control behavioral 
state (Huitron-Resendiz and others 2005), the uniqueness of its actions on PPN cholinergic 
neurons has been exploited in creating the fusion toxin, diphtheria toxin (Dtx) /UII (Clark and 
others 2007) (Table 2).  
Opioid peptides are expressed in rat PPN neurons (Fallon and Leslie 1986), including 
enkephalin and dynorphin, which may inhibit neuronal excitation, thereby modulating the 
release of neurotransmitters involved in pain relief and euphoria. Opioid peptides have also been 
implicated in the pathophysiology of PD, with Rinne and others (1983) reporting supersensitivity 
of enkephalin receptors in the striatum and limbic system of post-mortem PD brains. 
Calcium binding proteins 
Disturbed calcium homeostasis can render certain neurons vulnerable to neurodegeneration. As 
such, studies correlating expression profiles of calcium-binding proteins with different neuronal 
subtypes in the PPN at progressive stages of PD may be important in understanding local cell 
death. In squirrel monkeys, PPN cholinergic neurons express calcium-binding proteins such as 
calbindin (Côté and Parent 1992), while in cynomolgus monkeys a proportion of PPN 
cholinergic neurons co-express calretinin, another calcium-binding protein (Fortin and Parent 
1999). The calcium-binding albumin protein, parvalbumin, is expressed in rat PPN (Dun and 
others 1995), albeit at lower levels than calbindin and calretinin. Parvalbumin plays a key role in 
GABA neurotransmission, the main inhibitory neurotransmitter in the CNS. GABA release was 
increased in mice with reduced parvalbumin expression, prompting the suggestion that reduced 
parvalbumin expression may be a compensatory mechanism to enhance GABA release (Collin 
and others 2005). More detailed physiological and anatomical studies in experimental models of 
PD are awaited to elucidate how neurotransmitter release in the PPN, a calcium-dependent 
process, regulates specific behavior. 
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Neurochemical subdivisions of the PPN 
The PPN is classically defined as containing a pars compactus (PPNc), comprising the caudal 
half of the nucleus, and a pars dissipatus (PPNd), comprising the rostrocaudal axis of the PPN 
(Olszewski and Baxter 1982). The PPNs of rodents show a peculiar organization pattern: in rats 
the PPNd consists of an abundance of GABAergic neurons, but sparse populations of cholinergic 
or glutamatergics. In contrast, the PPNc contains a dense population of cholinergic and 
glutamatergic neurons, with a lower density of GABAergic neurons (Wang and Morales 2009; 
Mena-Segovia and others 2009; Martinez-Gonzalez and others 2012). It remains to be 
established whether the rostrocaudal distribution pattern for neurons with various 
neurotransmitter identities is rodent-specific or is repeated in human and non-human primates.  
Cholinergic neurons appear to be the most vulnerable (Pienaar and others 2013), although 
exactly why remains unexplained. One possibility is that only PPN cholinergic neurons contain 
NOS, which synthesizes the gaseous neuromodulator nitric oxide (NO). Neurons expressing 
NOS actively resist the toxic effects of excitatory amino acids (Contestabile and Ciani 2004) but 
can mediate excitotoxic damage at high concentrations (Dawson and others 1991). In this regard 
it is worth noting that a post-mortem study found that key proteins of the mitochondrial electron 
transport chain were significantly downregulated in PPN cholinergic neurons of PD but not 
control patients (Pienaar and others 2013). Since NO can trigger mitochondrial signal 
transduction events relating to cellular defense and –adaptation (Finocchietto and others 2009), it 
could be inferred that defective NO signaling, resulting in mitochondria-mediated cell arrest and 
programmed cell death could underlie PPN cholinergic neuronal loss in PD patients.  
Functional heterogeneity of the PPN 
The PPN is anatomically divisible into the PPNc and PPNd. Given that the PPN contains a 
neurochemically diverse neuronal population and has an extensive array of afferent and efferent 
connections, both ascending and descending, it is likely that further subdivision could eventually 
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become apparent. In this section we will examine PPN behavioral functions across species and 
the extent to which these can associate with particular PPN neurons. 
Behavioral state control  
The PPN seems to play a pivotal role in regulating sleep states. REM sleep resembles 
wakefulness, with similar cortical electroencephalogram (EEG) recording spectra. However, 
during REM sleep, but not the waking state, there is suppression of brainstem and spinal motor-
reflexes to stop movement being initiated. A high proportion of PPN cholinergic neurons send 
dual projections to the thalamus and pontine reticular formation (PRF), suggesting that the PPN 
has the potential to simultaneously modulate cortical activity via the thalamus, and motor 
activity via the PRF (Semba and others 1990; Lydic and Baghdoyan, 2003; Fuller and others 
2007).  
PD patients and animal models of PD present with a range of sleep-related symptoms, 
including excessive daytime sleepiness, a marked increase in the number of nocturnal 
awakenings and rapid eye movement (REM) sleep disorder (Gagnon and others 2002). In a 
striking demonstration of sleep dysfunction in an animal model of PD, Belaid and others (2014) 
performed long-term continuous EEG monitoring of vigilance states in macaques at baseline, 
after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intoxication, after administering 
Levodopa (at a clinically effective dose) as well as following cholinergic PPN lesions with 
Dtx/UII, selective for PPN cholinergic neurons (Table 2). MPTP intoxication resulted in 
excessive daytime sleep episodes, sleep fragmentation, a reduction of sleep efficiency, a 
reduction in time spent in REM- and slow-wave sleep, an increase in muscle tone during REM 
and non-REM sleep episodes and in the number of awakenings and movements during sleep. 
Levodopa treatment resulted in a partial but significant improvement in almost all sleep 
parameters, whilst the cholinergic PPN lesion produced a transient decrease in REM- and slow-
wave sleep, as well as slightly improved sleep quality.  
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Although involved, the PPN is not a master switch for sleep–wake transitions (Saper and 
others 2010). Excitotoxic lesions of the PPN have little effect on spontaneous sleep activity but 
do affect rats' ability to recover properly from sleep deprivation (Deurveilher and Hennevin 
2001). Traditionally the PPN is viewed as part of the ARAS, which is involved in sleep 
regulation, operating in parallel with brain systems in the hypothalamus and basal forebrain. 
Cholinergic neurons are the most numerous in the ARAS, found in both the PPN and the LDT, 
and referred to as the Ch5 and Ch6 groups respectively (Mesulam and others 1989). Using 
selective optogenetic activation in mice to clarify the role of cholinergic neurons in the PPN 
during REM sleep, Van Dort and others (2015) showed that selectively increasing cholinergic 
tone in the PPN or LDT during non-REM sleep increased the number of REM sleep bouts but 
did not affect REM episode duration. Notably though, the authors acknowledged that the 
transgenic mice used in the experiments, expressing an excitatory opsin in all cholinergic 
neurons, were found to express extra copies of the vesicular ACh transporter gene as well as 
showing increased cholinergic tone (Kolisnyk and others 2013).  
Sleep involves interactions between monoamine neurotransmitters of the ARAS and 
hypothalamic hypocretin neurons projecting to the PPN (Peyron and others 1998). Pal and 
Mallick (2006) showed in freely behaving rats that noradrenergic neurons projecting from the 
locus coeruleus to the PPN can tonically inhibit REM sleep. Likewise, Strecker and colleagues 
(1999) measured extracellular serotonin 5-hydroxytryptamine (5-HT)) levels in the PPN of 
naturally sleeping cats and found that levels were highest during wakefulness, lower during 
slow-wave sleep and lowest during periods of REM sleep. These results suggest that decreased 
5-HT levels in the PPN during sleep may be a critical determinant in timing REM sleep cycles. 
Studies have shown 5-HT’s potent hyperpolarization of cholinergic PPN neurons, a mechanism 
that appears central to presenting working models of REM sleep control (Leonard and Llinas 
1994). Bilateral PPN microperfusion of the serotonin type 1A (5-HT1A) receptor agonist, 8-OH-
DPAT, into rats revealed that 5-HT1A receptor-responsive PPN neurons become maximally 
  11  
active immediately before and during REM (Grace and others 2012). Note though that this result 
contradicts what was the prevailing model of REM sleep generation, which predicted that 
serotonergic inhibition of PPN neurons should suppress REM sleep (Thakkar and others 1998).  
Beyond the monoamine neurotransmitters of the ARAS, it is well established that GABAA 
ionotropic and ligand-gated ion channel receptors induce sleep, with several hypnotics targeting 
GABAA receptor-mediated inhibitory processes to decrease waking, increase slow-wave sleep 
and enhance the intermediate stage between slow-wave sleep and paradoxical sleep (reviewed by 
Gottesmann 2002). Some authors have suggested that REM sleep-active PPN neurons are 
predominately GABAergic (44-76%) (Maloney and others, 1999), and it has also been suggested 
that the physiological activity of GABA in the PPN is important for REM sleep. REM sleep was 
shown to be increased following intra-PPN microinjection of GABAA receptor agonists in freely 
moving rats (Pal and Mallick 2009). The same authors suggested that GABA could inhibit the 
release of noradrenaline for regulating REM sleep (Pal and Mallick 2006). The role of non-
cholinergic PPN neurons in behavioral state regulation was also highlighted by Verret and others 
(2005), with analysis of immediate early-gene expression to highlight neuronal activation which 
showed that in rats deprived of REM sleep, the vast majority of activated PPN cells were non-
cholinergic. Further studies are required to determine the role of different PPN neurons in the 
onset and maintenance of sleep architecture and the pathological mechanisms that underlie sleep 
disruption in PD. 
This brief summary presents a high-level view of how different neuronal-types in the PPN 
and their various inputs relate to the control of behavioral state. For more detailed information, 
readers should consult the recent comprehensive overview of the role of the entire ARAS in 
health and disease presented by Garcia-Rill (2015). 
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Locomotion 
The PPN has long been associated with movement. However, whether it is essentially a regulator 
of coordinated locomotion, part of what was termed the mesencephalic locomotor region, or 
whether it has a role in more complex processing, involving not just the initiation of locomotion 
but also action selection or decision making, remains to be firmly established. There are clearly 
connections between the PPN and motor control systems. Skinner and others (1990) established 
that the PPN can control locomotion via descending projections. PPN neurons that innervate 
motor structures are predominantly situated in the caudal part of the rodent PPN (Scarnati and 
others 2011) from where descending projections innervate the oral pontine reticular nucleus, the 
gigantocellular nucleus and the medioventral medulla. Projections to the spinal cord have also 
been described (Scarnati and others 2011). Other connections include the dentate nucleus of the 
cerebellum (Vitale and others 2016) and the vestibular system (Aravamuthan and Angelaki 
2012). All these connections to brain sites that are established regulators of motor functions are 
consistent with the idea that the PPN has a role to play in coordinated movement. Equally 
important, it has been established that muscle tone can be regulated by neurons in the PPN 
(reviewed by Takakusaki and others 2016). In human patients, neuronal activity has been 
recorded that shows PPN to be associated with gait (Tattersall and others 2014) and walking 
(Yeo and others 2011) and it is clear that PPN neurons are relevant to controlling locomotor 
activity. However, studies on experimental animals repeatedly illustrate that the relationship 
between the PPN and control of movement is not simple. The literature concerning non-primate 
experimental animals is clear and has been reviewed previously (Gut and Winn 2016). Briefly, 
excitotoxic lesions of the PPN using either ibotenate, N-methyl-d-aspartate (NMDA) or 
quinolinate did not impair either spontaneous or drug-induced whole body locomotion. 
Excitotoxic lesions also did not impair reaching or grasping (Dunbar and others 1992), gait or 
posture (Gut and Winn 2015) (Figure 4 provides examples of tests for measuring a broad range 
of motor and cognitive behavioral domains in rodent models of PD). Examination of the effects 
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of excitotoxic lesions on non-human primate PPNs have produced clear data, but conflict with 
the outcomes of studies that made use of other species. Studies have demonstrated motor 
impairments following kainate-induced excitotoxic lesions (Kojima and others 1997; Munro-
Davies and others 1999). However, due to its extreme potency, no study yet has utilized kainate 
for lesioning the rodent PPN to study the impact on locomotion. As such, whether the data 
gathered from non-human primate studies reflects a genuine species difference (compared to 
rodents) or is simply due to different experimental methodologies, remains uncertain. For further 
discussion of this matter, see Gut and Winn 2016. 
Interestingly, a recent study suggests that the PPN has a role in relation to movement and 
navigation. Navigation is thought to rely on interplay between the medial entorhinal cortex 
(MEC) and hippocampus. The MEC contains grid cells which systematically represent an 
animal's displacement in the environment. Alongside these (to enable proper use of positional 
representation by grid cells) are neurons whose activity relates to running speed (Kropff and 
others 2015). A likely source of information regarding locomotor speed is the PPN. 
Electrophysiological single-unit activity recordings made in rats performing a spatial navigation 
task (Norton and others 2011) showed that a substantial proportion of PPN neurons held a 
correlation between firing rate and velocity, with this correlate that was unaffected by the spatial 
context, including reward. Similarly, Lee and others (2014) showed a relationship between 
running stimulated from the region of the PPN and cortical activity in mice. Rats bearing PPN 
excitotoxic lesions were substantially impaired in making appropriate choices in an 8-arm radial 
maze but were quicker than controls in moving from arm to arm (Keating and Winn 2002), 
possibly suggesting that PPN neurons normally brake run speed. In a simple runway task, 
similarly lesioned rats were able to increase running speed when reward value increased (Ainge 
and others 2006), suggesting that while decision making was impaired, motivation to run was 
unaffected.  
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Axial motor functions 
Although PD-related motor symptoms respond well to dopamine replacement therapy, axial 
abnormalities including gait dysfunction, gait freezing and postural instability, respond poorly. 
The PPN has been adopted as a therapeutic target but its role in gait pathology is disputed. A 
recent study in PD patients showed PPN-DBS having no effect on gait parameters, although the 
intervention improved anticipatory postural adjustments and gait postural control (Collomb-
Clerc and Welter 2015). This contrasts with DBS of the subthalamic nucleus (STN) and globus 
pallidus interna (GPi), which did improve gait in PD patients (Weiss and others 2015) (Figure 2; 
Table 1). Interestingly, Weiss and colleagues (2015) noted a correlation between improvement in 
imagined gait during STN-DBS and an increase in regional cerebral blood flow in a brain region 
which includes the PPN. Whether this implicates the PPN as a gait modulator of STN-DBS or 
whether it reflects a more general activated state remains to be determined. 
Given the inconsistent patient data, a number of labs have used animal models to better 
understand the role the PPN plays in the behavioral features of PD. We focus on three recent 
approaches: (1) DBS in rats bearing combined dopamine depletion and PPN lesions; (2) the 
lactacystin rat model of PD (Table 2), and (3) use of the fusion toxin Dtx/UII. 
PPN-DBS was studied by Gut and Winn (2015) who analysed gait in rats harboring either 
partial or full bilateral PPN ibotenate lesions. Lesioned rats were then bilaterally implanted with 
wireless DBS electrodes in either anterior or posterior PPN (corresponding approximately to the 
PPNd and PPNc, respectively) for chronic stimulation using clinically-relevant frequencies. The 
PPN was found to not be critical for normal gait, with addition of a partial PPN lesion to a 
dopamine-depleting nigral one that did not worsen gait parameters further than those produced 
by dopaminergic depletion alone. The combined lesion model showed a correlation between 
cholinergic survival and a deficit in forelimb gait stability, but not other parameters. However, 
the group that received the combined partial PPN lesion and striatal dopamine depletion showed 
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pronounced freezing of gait (FOG). In addition, in dopamine-depleted rats with an intact PPN, 
posterior PPN-DBS ameliorated some gait deficits, whilst anterior PPN-DBS worsened FOG. 
Gait disturbance is not considered to be purely a motor phenomenon but a complex interplay 
between motor, cognitive and affective factors (Heremans and others 2013), which may explain 
why FOG was not visible when rats were in their home cages, only becoming apparent when 
they were in the narrow test runway.  
Pienaar and others (2015a) showed that rats intranigrally (unilaterally) infused with the 
proteasome inhibitor lactacystin manifest severe motor disabilities in tasks involving the 
contralesional fore- and hindlimbs. The lesion resulted in destruction of SN dopaminergic 
neurons (Vernon and others 2011; Pienaar and others 2015a), as well as neurons in the 
adjacently-lying PPN (Pienaar and others 2015a). Further work revealed that lactacystin toxicity 
was not specific to cholinergic neurons when administered in vivo to rats (Elson and others 
2015) but overexpression of the presynaptic protein α-synuclein (resembling Lewy body 
pathology seen in parkinsonism) predominantly accumulated within PPN cholinergic neurons 
rather than non-cholinergic ones. Direct stimulation of remaining PPN cholinergic neurons in 
rats that had been intra-nigrally lesioned with lactacystin was achieved using hM3Dq. 
Essentially a floxed muscarinic G protein-coupled receptor, with the coding gene modified via 
insertion of 2 point-mutations (a so-called Designer Receptor Exclusively Activated by Designer 
Drug (DREADD)), to allow for neuronal depolarization upon binding to the ligand clozapine-N-
oxide (CNO) (Figure 3). Rats were ChAT::Cre+, so that all cholinergic neurons expressed Cre-
recombinase, restricting hM3Dq expression to cholinergic neurons. This cholinergic-specific 
excitation of remaining PPN cholinergic neurons dramatically reversed parkinsonian-like motor 
deficits, particularly gait and postural instability (Pienaar and others 2015b).  
The fusion toxin Dtx/UII has been used to examine normal functions of PPN cholinergic 
neurons. A study by Karachi and others (2010) revealed gait and postural deficits by macaques 
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after injection of Dtx/UII, accompanied by cholinergic and non-cholinergic neuronal damage in 
the PPN. The authors suggested that the loss of non-cholinergic PPN neurons may have been 
secondary to the primary loss of PPN cholinergic neurons, but caution in interpretation is 
required since the concentrations of Dtx/UII used (and at which behavioral deficits appeared) are 
known to generate non-selective lesions in rodent. Studies reporting cholinergic-selective lesions 
in rats showed no impairments in spontaneous or nicotine stimulated locomotion, or learning 
impairments (MacLaren and others 2016). With regards to drug rewards, Steidl and colleagues 
(2014) showed that there was no impairment in performance despite almost complete cholinergic 
neuronal loss being accompanied by significant loss of PPN glutamate and GABA containing 
neurons. This low degree of selectivity was possibly a product of employing multiple rather than 
single toxin injections, with larger doses causing non-selective damage (Clark and others 2007). 
Other studies reported that motor deficits appear after Dtx/UII lesions, including impairments in 
the accelerating rotarod test at higher speeds and in fine motor control (MacLaren and others 
2014a). These might reflect specific motor problems, but could alternatively be accounted for by 
disruption of the attentional processes required for these tasks. In this regard, deficits in 
sustained attention (Cyr and others 2015) and acoustic startle responding have both been 
reported after Dtx/UII lesions (MacLaren and others 2014b).  
The question raised at the start of this section was whether the PPN is essentially a regulator 
of coordinated locomotion or whether it has a more complex role in generating actions. The 
underlying neural substrate for the effects described here likely involves extensive reciprocal 
connections with corticostriatal systems, with implications for cognition and emotional 
reactivity. Given the damage to dopamine-containing neurons in both the lactacystin and PPN-
DBS studies, one possible explanation for the effects of PPN-DBS and for the restorative power 
of DREADD-mediated cholinergic activation after lactacystin lesioning is stimulation of 
ascending cholinergic projections to the thalamus. Such stimulation might correct dysfunctional 
oscillatory activity in corticostriatal circuits, known to be essential for producing coordinated 
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movement (Brown 2007). This would be consistent with the deficits in attention and acoustic 
startle reactivity that follow Dtx/UII lesions in PPN. It would be intriguing to know whether 
DREADD-mediated restoration of movement is accompanied by restoration of both 
corticostriatal oscillatory activity and the cognitive deficits that appear after dopamine-depleting 
lesions. Figure 4 gives examples of tests used for measuring specific motor behavioral domains 
in rodent models of PD, including for assessing the axial parkinsonian symptoms referred to in 
this section.  
Cognitive functions 
For many neuroscientists the idea that the PPN, a brainstem structure, is involved in cognitive 
functions will be surprising, but data from PPN-DBS studies in parkinsonian patients and a 
wealth of literature using experimental animals evidence this convincingly. Electrophysiological 
data from primates and rodents shows complex processing. An early primate study demonstrated 
that arm movements relate to firing of PPN neurons (Matsumura and others 1997) but later work 
by Okada and others (2009), also recording from the non-human primate PPN revealed more 
complex responses, with PPN neurons responding to either the predicted or actual scale of 
rewards. These are not intrinsically motor signals and hint strongly at more subtle processes 
occurring in the non-human primate PPN.  
Similar predictive responding by PPN neurons has been shown in rodents. Norton and others 
(2011) recorded from rat PPN neurons and correlated reward acquisition (which was sensitive to 
changes in context), speed and direction. The authors concluded that PPN neurons played a role 
in sensory-motor gating and were involved in reinforcement learning. Later work from the same 
group (Redila and others 2015) showed that neurons in the LDT were also responsive to 
movement and reward but were less influenced by current sensory input. Similarly, Thompson 
and others (2016) showed that PPN neuronal activity related to decision making. In particular, at 
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the point of action selection, mouse PPN neuronal activity related to the previous choice and its 
outcome, with the strength of this response that predicted the next decision.  
Although none of these studies were able to identify the neurochemical identity of the 
neurons being recorded, they highlight the fact that computations occurring in the PPN and LDT 
do not only relate to sleep or movement per se, but rather indicate complex integrative 
properties. The electrophysiological data are supported by numerous lesion studies. Over the last 
20 years a variety of studies from multiple labs using excitotoxic lesions (which, as noted above, 
do not effect basic locomotor functions) show that the PPN has a role in reward and 
reinforcement (Olmstead and Franklin 1994), learning and memory (Keating and Winn 2002; 
Wilson and others 2009; MacLaren and others 2013) and attention (Inglis and others 2001; 
Kozak and others 2005). Such discoveries in experimental animals are matched by clinical 
studies on PD patients who underwent PPN-DBS. As noted above, as well as effecting sleep 
structure (Alessandro and others 2010) this treatment has led to improved verbal fluency and use 
of language (Zanini and others 2009) and improved performance in working memory tasks 
(Alessandro and others 2010). 
Many PD patients suffer from dysexecutive syndrome, with some studies suggesting that 
PPN-DBS in advanced PD patients ameliorates executive function deficits, along with improving 
delayed recall and verbal fluency (Alessandro and others 2010). In another study, PD patients 
that had received bilateral stereotactic PPN implantations were subjected to 18-fludeoxyglucose 
(18F)-Positron Emission Tomography (PET) for identifying sites of abnormal glucose 
metabolism. Using a battery of cognitive testing, Ceravolo and others (2011) showed that 
delayed recall and executive functions improved as a result of bilateral low frequency 
stimulation (LFS)-PPN in PD patients. In the same study, these authors also showed increased 
glucose utilization in bilateral prefrontal areas as well as in the left ventral striatum, left 
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subgyral, right insula and right superior temporal gyrus, strongly supporting the contention that 
PPN stimulation improves cortical function.  
Of particular interest to this review are studies that looked at the effects of excitotoxic lesions 
in restricted areas of the PPN, and studies that attempted selective destruction of cholinergic 
neurons. Ibotenate lesions of the posterior but not anterior PPN disrupt nicotine self-
administration, perhaps unsurprisingly given the density of PPN cholinergic neurons (Alderson 
and others 2006). Rats with similar lesions of the posterior PPN were slower at learning to lever 
press with food reinforcement and had lower rates of lever pressing. Those with anterior PPN 
lesions worked at normal rates for food reinforcement but tended to perseverate and make 
anticipatory errors, and also persisted with responding in extinction (when no reinforcement was 
present and terminating lever pressing was appropriate). These deficits were characterized by 
Wilson and others (2009) as indicative of learning impairments mediated by the posterior PPN 
with the anterior PPN involved in selecting appropriate and avoiding inappropriate actions. This 
is supported by a study showing that inactivation of the posterior PPN by local injection of the 
selective GABAA receptor agonist, muscimol, impairs performance in a contingency degradation 
programme, which is taken as a key indicator of action-outcome association learning (MacLaren 
and others 2013). However, studies with the selective fusion toxin Dtx/UII cloud this picture, 
with such lesions having no effect on learning to lever press for food rewards (MacLaren and 
others 2016) but having effects consistent with impaired attention, as noted above (Cyr and 
others 2015). Overall, the data shows there are regional differences in PPN function: non-
selective lesions of the posterior but not anterior PPN create clear learning deficits, but lesions 
that destroy only the cholinergic population of the posterior PPN produce attentional deficits, 
with no impact on learning ability per se. One might speculate that the posterior PPN (PPNc) 
cholinergic neurons therefore regulate attentional functions, posterior PPN non-cholinergic 
neurons are involved in learning and that anterior PPN (PPNd) non-cholinergic neurons are 
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involved with response selection. Examples of tests designed to assess cognitive behavioral 
domains relevant to PD in rodent models of the disease are illustrated in Figure 4.   
Conclusions 
The heterogeneous cellular architecture of the rodent PPN is topographically organized, 
reflecting its functional diversity. The neurochemical types are widely distributed and 
intermingled, but can also be seen to define subterritories, particularly along a rostrocaudal axis. 
The data from animal models have started to unpack the relationships between PPN regions and 
different neurochemically identifiable neurons within them. Critical here though has been the 
discovery – reinforced by PPN-DBS studies in patients – that the PPN has functions not only 
related to behavioral state control and movement but also to cognitive processes. For the 
immediate future, the PPN will remain the subject of intense study, as understanding of the role 
of its diverse neural elements in controlling behavior continues to expand. Central to this 
understanding is the accurate description of its complex organization. Optogenetic and 
chemogenetic techniques will almost certainly play an important role in coupling structure to 
function and may go on to fulfill a translational role, at the very least as an alternative to 
electrode-based DBS. 
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Figure legends 
Figure 1:   An overview of the major efferent projection pathways originating in the PPN, with 
information on their neurochemical identity. In rats, the PPN sends ascending efferent fibers to 
the thalamus and the basal ganglia complex, which travel via the ansa lenticularis and the 
lenticular fasciculus. Further ascending efferents from the PPN include the entopeduncular 
nucleus (EP, homologous to the GPi in primates) and SNpc. Descending efferents project to the 
cerebellum, reticular formation (RF), locus ceruleus (LC), raphe nuclei (RN) and spinal cord 
(SC). Arrow colors represent the main neurochemical phenotype of the neuronal projections, but 
the neurochemical nature of the majority of PPN projection neurons remain to be fully identified 
(black arrows indicate that these have only so far been identified as being ‘non-cholinergic’). 
The figure also shows the differential distribution of neurons within the PPN according to 
neurotransmitter expression, along the rostrocaudal axes of the PPN, which divides the PPN into 
the PPNc and PPNd. The distribution gradients of prominent neuronal populations (cholinergic 
(green), glutamatergic (blue), GABAergic (red) neurons and unspecified neurochemical cell type 
(black)) indicate functional territories within the PPN, with each neuronal subgroup 
demonstrating unique connectivity to neuronal structures involved in regulating specific 
behavioral effects. In rats, using the accepted means of defining the PPN borders according to 
the cholinergic (Ch5) neurons, total unilateral PPN neuronal counts have been estimated at 
~19,028 (Pienaar and van de Berg 2013). Of these, the GABAergic population is highest at the 
rostral pole, contrasting to the glutamatergic and cholinergic neuronal groups, which are more 
densely concentrated at the caudal pole of the nucleus (Wang and Morales 2009; Mena-Segovia 
and others 2009). Discrepancy exists relating to the estimated number of cholinergic and non-
cholinergic neurons in the human PPN, due in large-part to the ill-defined boundaries of the PPN 
in humans (Jenkinson and others 2009). See text for further discussion. Abbreviations used: 
Cerebral cortex, Cerebral cx; Entopeduncular nucleus, EP; Inferior colliculus, IC; Lateral 
hypothalamus, LH; Locus ceruleus, LC; PPN pars compactus, PPNc; PPN pars dissipates, PPNd; 
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Raphe nuclei, RN; Reticular formation, RF; Spinal cord, Sc; Substantia nigra pars compacta, 
SNpc; Subthalamic nucleus, STN; Superior colliculus, SC; Ventral tegmental area, VTA. 
Figure 2:   DBS is a well-established therapeutic option for PD patients. A more tailored 
approach to DBS therapy, encompassing all potential combinations of stimulation parameters 
(contact, voltage, pulse width, pulse frequency) improves overall patient outcomes. When 
formulating a DBS treatment plan, patient symptoms guide target choice. The figure portrays the 
four possible brain target sites for placement of stimulating electrodes (orange), namely (A) the 
ventrolateral subdivision of the thalamus, also referred to as the ventral intermediate nucleus 
(Vim), (B) the STN, (C) the GPi and (D) the PPN. Abbreviations used: Central tegmental tract, 
CTT; Cranial nerve, CN; Decussation of the superior cerebellar peduncle, SCP, Dec; Globus 
pallidus externa, GPe; Globus pallidus interna, GPi; Lateral lemniscus, LL; Medial lemniscus, 
ML; Spinothalamic tract, STT; Substantia nigra pars reticulata, SNr. 
Figure 3:  (A) Mechanism of action for DREADDs in controlling activity of specific cell types 
in the brain. DREADDs belong to the metabotropic class of receptors that use G proteins as their 
signaling mechanism and are dubbed hM3Dq (human M3 muscarinic DREADD 
receptor coupled to Gq signaling) and hM4Di (human M4 muscarinic DREADD 
receptor coupled to Gq signaling). Upon being activated by an agonist, G protein-coupled 
receptors (GPCRs) interact with the trimeric G-protein alpha/beta/gamma complex. The figure 
illustrates the GPCR’s seven transmembrane domain structure, into which two point-mutations 
(red arrows) have been inserted, causing a loss of responsiveness to the cognate agonist ACh. 
However, when such mutant GPCRs are expressed in a particular tissue, the ligand CNO can 
activate the mutant receptor, with in vivo activation of neurons overexpressing hM3Dq that 
induces neuronal excitation through whilst CNO activation of neurons overexpressing hM4Di 
that induces neuronal silencing by hyperpolarizing and attenuating neuronal firing. In 
experimental animals, use of Cre-dependent adeno-associated viruses by which to restrict 
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DREADD expression to cells that selectively express Cre selectively is an increasingly popular 
method expressing DREADDs in specific cell populations. Spatial specificity of DREADD 
expression can be further refined through stereotaxic microinjection of the virus into a target 
region. Ultimately, behavior change is monitored as this represents the output of specific cells, 
which are manipulated using a DREADD-CNO approach. CNO possesses excellent oral 
bioavailability and CNS penetration; hence DREADDs offer a means for remotely-induced 
stimulation/inhibition in different neuronal types that are interdigitated in the same brain areas 
e.g. the PPN. (B) The left figure illustrates the highly non-specific stimulation that is applied to 
all cell types within the stimulation target. On the other hand, as shown on the right, DREADDs 
offer more specific effects than electrical stimulation, by altering the firing of specific neuronal 
types to evoke a change in the behavior of experimental animals and ultimately perhaps in 
humans also; hence offering an alternative to DBS. However, a significant barrier before 
DREADD-based therapeutic approaches can reach their full potential is presented by the 
challenge of virally expressing designer receptors in adult human neurons.  
Figure 4:  The images portray standardized behavioral tests to measure, in animals that model 
PD, the functional deficits resulting from damage to the CNS. Development of such tests 
represents efforts to obtain objective and quantitative readouts. (A - E) Motor tests provide a 
good read-out of neurological function. Several well-validated tests have been developed that 
assess motor phenotype in rodents, with impaired locomotor function that is evaluated by using 
scoring systems or biomechanical measures. (A) This test assesses balance impairment as an 
axial symptom of PD resulting from the loss of postural reflexes, seen during the later stages of 
PD. (B) A sensitive and easy to execute test for detecting sensorimotor function, by assessing the 
ability of rodents to reliably place a forelimb on a tabletop, when the contralateral vibrissae are 
contacted. (C) Gait impairment, including shuffling, short steps and slow walking speed features 
frequently in PD patients and is mimicked in rats rendered hemiparkinsonian via stereotaxic 
intracranial delivery of toxins. To record gait pattern changes in rats, several investigative 
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systems have been developed, the most conventional being use of footprint analysis, where an 
animal’s paws are covered by ink, to create footprints on a paper strip, as the animal traverses a 
narrow walking track. (D) This test exploits the natural exploratory tendency of rodents by 
evaluating its spontaneous forelimb use and how this is impaired in motor system injury models 
that depict stroke and PD. For this, an animal is placed in a transparent Plexiglas cylinder for 
observations. (E) Motor coordination can be assessed in rodents by means of the rotarod test, 
where the animal is placed on a horizontal rod that rotates about its long axis. In order not to fall 
off, the animal must walk forward. Two versions of the rotarod, set- and accelerating speed, is 
available. (F - I) Many behavioral paradigms have been developed to examine the contribution 
of various neural systems implicated in learning and memory function in rodents. (F) Rodents 
have a natural exploratory drive to explore new environments (for food and shelter) and to avoid 
open and brightly lit spaces (exposure to predators). By placing rodents into a relatively large, 
brightly lit novel context of a circular or rectangular shape, locomotor activity, exploratory drive, 
neophobia and certain aspects of anxiety are measured. (G) Rodents are deemed to display 
anxiety-like behavior when it spends an increased amount of time and makes multiple entries 
into the closed arms (that represent rodents’ preference for protected areas) of the elevated plus 
maze. In contrast, its innate motivation to explore novel environments is measured as activity in 
the open arms of the maze. (H) A test of spatial learning, where rodents are tasked at locating a 
submerged escape platform in an opaque swimming pool, by relying on distal navigation cues 
placed around the perimeter of the swimming arena. As performance in this task requires 
strength and coordination, evaluators need to dissect out the motor from the cognitive 
impairments when assessing rodent models of neurological disease. Although a detailed 
explanation of the procedures used in executing the tests exemplified here lies outside the scope 
of the current article, we refer the interested reader to articles that review behavioral outcome 
measures used in animal models of PD (e.g. Bury and Pienaar 2013; Pienaar and others 2012). 
(I) A cognitive function (especially executive function, learning and memory) assessment tool 
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based on rodents that interact with an automated touchscreen platform, which is gaining 
popularity, as various assays can be run similarly to human subjects, thereby allowing 
translation of laboratory animal results to humans. A positive (appetitive) reinforcement, rather 
than an aversive one is used for stimulating performance, which minimizes stress in the animals. 
Further information and precise protocols for performing touchscreen assays using experimental 
animals can be found in Horner and others (2013).  
Table 1:   A summary of the different sites for implantation of a DBS electrode for alleviating 
PD symptoms. Target choice and optimal stimulation parameters should be tailored to a patient's 
individual needs. Although rare, practitioners should be aware that the procedure is not risk free, 
but candidacy for DBS surgery should be deemed based on whether a patient’s needs and 
expected benefits outweigh the risks of surgery. Information presented in the table are discussed 
in detail in several recent review articles. The interested reader is referred to Papageorgiou and 
others (2016) and Verhagen Metman and others (2016). 
Table 2:   Toxins that recognize a broad range of cell types including neuronal cells, but show 
preferential toxicity for specific neurons, with this feature that can be exploited for studies 
investigating the relative contribution made by these neurons towards behavior mediated by the 
PPN.  
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Table 1: 
 
Target 
(and key 
reference) 
Major 
indications 
Electrical 
stimulation 
parameters 
Potential side-
effects resulting 
from the DBS 
procedure 
Contraindications 
Vim nucleus 
of the 
Thalamus 
 
 PD with 
essential 
tremor 
 PD with 
orthostatic 
tremor 
High 
frequency 
stimulation 
 Surgery-related 
complications 
o Minimal 
tissue damage 
o Intracerebral 
hemorrhage 
o Chronic 
subdural 
hematoma 
 Device-related 
complications 
o Device 
infection 
o Pulse 
generator 
malfunction 
 Stimulation-
related 
complications 
o Intractable 
dyskinesia 
o Apraxia of 
eyelid opening 
o Back pain 
o Restless leg 
syndrome 
 Psychiatric 
symptoms 
o Impulse 
control 
disorder 
o Depression 
(most 
common) 
o Delusion 
o Euphoria 
o Disinhibition 
o Suicide 
attempts 
 Other 
o Tolerance 
may develop 
in patients that 
require 
adjustment of 
stimulation 
parameters 
 Non-drug 
induced 
preoperative 
psychiatric and/ 
cognitive 
dysfunctions 
 Caution should 
be applied in PD 
patients co-
diagnosed with 
diabetes 
(increased 
predisposition for 
device-induced 
infection) 
and/hypertension 
(increased 
predisposition for 
intraoperative 
hemorrhage from 
implanting a 
DBS electrode) 
STN 
 
 PD with 
rigidity 
 PD with 
tremor 
 PD with 
slowness of 
movement 
(bradykinesia) 
High 
frequency 
stimulation 
 
GPi  PD with 
dystonia 
 PD with 
tremor 
 PD with 
rigidity 
 PD with 
bradykinesia 
 PD with 
dyskinesia 
 PD with gait 
difficulties 
High 
frequency 
stimulation 
PPN 
 
PD with FOG Low 
frequency 
stimulation 
 
 
  45  
Table 2: 
 
Toxin Source Toxic mode of 
action 
Cellular specificity 
Diphtheria toxin – 
Urotensin II  
(Dtx-UII) 
 
Diphtheria toxin 
fused to 
urotensin-II 
(Clark and others 
2007) 
 
 
Dtx-UII comprise 
of the endogenous 
ligand for 
urotensin-II 
receptors that are 
expressed by PPN 
cholinergic neurons 
but not by 
glutamatergic or 
GABAergic ones. 
Cholinergic neurons. As with 
other fusion toxins, high doses 
can cause death of other 
neuronal types. 
Lactacystin Bacteria 
belonging to the 
genus 
Streptomyces 
Inhibits the 
proteasome, with 
clasto-lactacystin β-
lactone that 
comprise the cell-
permeable, active 
form of lactacystin.  
 
Several studies have shown that 
lactacystin’s effect extend 
beyond the injection site and 
exerts a weaker toxic effect on 
non-dopaminergic than 
dopaminergic neurons. In rats, 
stereotaxic lesioning of the 
nigrostriatal system results 
in destruction of dopaminergic 
neurons and formation of 
ubiquitin/α-synuclein 
immunopositive inclusions in 
surviving ones (McNaught and 
others 2002). Lactacystin was 
not fully selective 
to dopaminergic neurons, but 
also moderately reduced the 
number of non-dopaminergic 
ones in the SN (Konieczny and 
others 2015). This study also 
showed slightly reduced GABA 
levels in the SN following the 
lesion, while others showed that 
striatal GABA medium spiny 
neurons appear resistant to this 
toxin, when delivered in vivo 
(Lorenc-Koci and others 2011). 
As an example of the toxin’s 
effects beyond the injection site, 
Harrison and others (2016) 
observed neurodegeneration 
within the SN, and degeneration 
of dopaminergic neurons of the 
nearby ventral tegmental area 
(VTA). However, loss of VTA 
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dopaminergic neurons was less 
severe than in the SN pars 
compacta. When injected 
directly into the rat SN, 
preferential retrograde toxicity 
is shown towards cholinergic 
neurons in the PPN with less 
destruction of PPN non-
cholinergic neurons (Elson and 
others 2015). 
It is likely that lactacystin’s 
selectivity with regards to 
neuronal types and brain region 
depends on the dose and 
infusion rate; aspects which 
require further investigation in 
future studies. 
MPTP  
(1-methyl-4-
phenyl-1,2,3,6-
tetrahydropyridine) 
A street-drug 
contaminant de-
riving from un-
derground labora-
tory preparations 
of a potent analog 
of meperidine 
(Demerol). 
MPTP itself does 
not appear to be 
toxic, but its oxi-
dized product (1-
methyl-4-
phenylpyridinium 
(MPP+)), is toxic. 
Energy-driven mi-
tochondrial uptake 
of MPP+ results in 
sufficiently high 
concentrations of 
the toxin to inter-
fere with mitochon-
drial respiration in 
the cell. 
Appears to specifically target 
neurons involved in PD pathol-
ogy, including nigrostriatal do-
paminergic and brainstem cho-
linergic neurons 
Excitotoxins 
The most 
commonly used are 
ibotenic acid 
(ibotenate), kainic 
acid (kainate), 
N-methyl-D-
aspartate (NMDA) 
and quinolinic acid 
(quinolinate) 
Rigid structural 
analogs of 
glutamate, 
derived from 
various sources. 
Ibotenate is a 
secondary 
metabolite of the 
mushroom 
Amanita 
muscaria; kainate 
is found in 
seaweeds; 
NMDA is a 
synthetic product, 
not naturally 
Binding to 
glutamate receptors 
typically result in 
increased influx of 
chloride and 
calcium ions, 
excess water entry, 
to finally result in 
osmotic lysis of 
cells. Different 
excitotoxins have 
different binding 
profiles to the 
various types of 
glutamate receptor 
and are effective at 
Excitotoxins cause neuronal 
death but spare fibers of 
passage (e.g. Brace and others 
1997). 
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found in 
biological tissues; 
quinolinate is 
naturally 
synthesized in the 
kynurenine 
metabolic 
pathway. 
different 
concentration 
ranges.  
Transient lesions 
using muscimol 
Muscimol is a 
natural psychoac-
tive constituent 
of the mushroom 
species Amanita 
muscaria (as is 
ibotenic acid) and 
Amanita pan-
therina. 
A potent GABAA 
receptor agonist, 
with GABAA com-
prising the receptor 
for GABA, the 
CNS’s principal 
inhibitory neuro-
transmitter. 
It is used as a de facto transient 
lesion. By acting as a GABA 
agonist, muscimol inhibits all 
neurons in the region of injec-
tion. Unlike a local anesthetic, it 
does not affect local fiber sys-
tems. 
 
 
 
